Compare ARWR & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARWR | CHRD |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | 676 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.2B |
| IPO Year | 2009 | N/A |
| Metric | ARWR | CHRD |
|---|---|---|
| Price | $73.24 | $136.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $83.40 | ★ $149.17 |
| AVG Volume (30 Days) | ★ 1.6M | 706.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,142,321.00 | N/A |
| Revenue This Year | N/A | $12.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $353.91 | ★ $34.53 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.30 | $84.25 |
| 52 Week High | $79.48 | $150.50 |
| Indicator | ARWR | CHRD |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 48.47 |
| Support Level | $60.60 | $99.43 |
| Resistance Level | $76.45 | $148.42 |
| Average True Range (ATR) | 3.58 | 4.53 |
| MACD | 0.04 | -0.54 |
| Stochastic Oscillator | 40.58 | 39.28 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.